Thomas Turi, Ph.D. joined the executive leadership at Nexelis in the role as Chief Scientific Officer. Dr. Turi brings 25 year’s pharmaceutical and contract research leadership experience. Two of Dr. Turi’s previous accomplishments are when he established the Biomarker Center of Excellence for Covance, and when he served as Senior Director of Translation Biomarkers and Mechanistic Biology at Pfizer.

In addition to his current responsibilities, Dr. Turi has served on the Board of Trustees for The Life Sciences Foundation and is a member of the Global Health Research Roundtable of the Indiana Clinical and Translational Sciences Institute. He has previously served on the Board of Directors for Caprion Proteomics and led several external partnerships including those with Rules Based Medicine, Celera, Incyte, and Affymetrix. He has also served on grant and program project review boards for NASA’s Section for Biotechnology and Tissue Engineering. Dr. Turi received bachelor’s degrees in Biochemistry and Chemistry from the University of Illinois at Urbana-Champaign and his doctorate in Molecular Genetics from the University of Cincinnati College of Medicine. He completed postdoctoral training at the Yale University School of Medicine applying molecular genetic techniques to investigate the mechanisms of protein transport.